Stem Cell Surgery Helps Boy With Spina Bifida Walk at 4

When Michelle Johnson learned at 20 weeks pregnant that her son had spina bifida, she faced a heartbreaking reality: without surgery, her baby would likely never walk. His spine hadn't sealed properly, leaving his spinal cord exposed and vulnerable to permanent damage.

Johnson enrolled in an experimental trial at UC Davis that changed everything. Surgeons performed delicate fetal surgery at 24 weeks, placing a small patch loaded with stem cells directly onto her unborn son's damaged spinal cord.

Today, four-year-old Tobi runs and plays like other kids his age. He has full bladder and bowel control, abilities that seemed impossible before treatment.

The CuRe trial marks the first time doctors have safely used stem cells to heal tissue in the womb. Six babies participated in this initial safety study, and none experienced complications like infection, unwanted tissue growth, or cancer.

Traditional fetal surgery for spina bifida already helped many babies, but over half still couldn't walk without assistance. The added stem cells appear to make the crucial difference by protecting neurons from damage and releasing growth proteins that help the spinal cord heal.

The journey to this breakthrough took years of persistence. The research team first tried using induced pluripotent stem cells created from skin cells, but those didn't work. They found success with stem cells derived from donated placental tissue, which protected and encouraged neuron growth in lab tests and animal models.

Why This Inspires

This trial represents hope for the roughly 350 American families who receive a spina bifida diagnosis each year. What once meant a lifetime of surgeries, mobility aids, and medical complications could become a one-time fix before birth.

The success extends beyond spina bifida. Researchers are now testing prenatal stem cell treatments for blood disorders like thalassemia and brittle bone disease, conditions that start before babies take their first breath.

Lead investigator Diana Farmer captured the magnitude perfectly: "Putting stem cells into a growing fetus was a total unknown." The fact that all six babies thrived without complications cleared a major hurdle for expanding this approach.

The FDA has already approved enrolling more pregnant women in the trial based on these promising safety results. Each new participant brings researchers closer to understanding whether stem cells consistently improve outcomes beyond what surgery alone achieves.

For families like the Johnsons, the science translates into something beautifully simple: watching their son walk, run, and play without limitations they once thought were inevitable.